Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider – Zacks.com
Philadelphia Business Journal |
Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider
Zacks.com Gilead Sciences's (GILD – Free Report) Yescarta, a cell-based gene therapy, gained approval for the treatment of adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of … FDA approves second gene-altering treatment for cancer US approves second gene therapy against cancer FDA Approves Second CAR-T Therapy In US To Gilead's Kite Pharma |
